- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Review, Journal: Platelets, Thromboinflammation and Neurovascular Disease. (Pubmed Central) - May 6, 2022
Furthermore, the clinical importance of neuroinflammatory mediators and a potential translational relevance of involved mechanisms are addressed also with focus on non-classical immune cells including microglia cells or platelets. As illustrative examples, novel agents such as Anfibatide or Revacept, which result in reduced recruitment and activation of platelets, a subsequently blunted activation of the coagulation cascade and further inflammatory process, demonstrating that mechanisms of neuroinflammation and thrombosis are interconnected and should be further subject to in depth clinical and basic research.
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Journal: The antiplatelet agent revacept prevents the increase of systemic thromboxane A biosynthesis and neointima hyperplasia. (Pubmed Central) - Mar 25, 2021
The administration of the novel antiplatelet agent Revacept to C57BL/6 mice, beginning three days before femoral artery denudation, and continuing up to seven days after injury, prevented the increase of the systemic biosynthesis di TXA and reduced femoral artery intima-to-media area and the levels of markers of cell proliferation and macrophage infiltration. Revacept might serve as a therapeutic agent for percutaneous coronary angioplasty and stent implantation.
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Clinical, P2 data, Journal: Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial. (Pubmed Central) - Dec 5, 2020
The efficacy of Revacept was evaluated by exploratory assessment of new diffusion-weighted imaging lesions on magnetic resonance imaging after the revascularization procedure; a combination of cardiovascular events (ischemic and hemorrhagic stroke, TIA, myocardial infarction, or coronary intervention) and bleeding complications served to assess clinically critical patients' outcome and safety. This exploratory phase II randomized, double-blind clinical trial provides valuable insights on the safety, tolerability, and efficacy of Revacept in patients with symptomatic carotid artery stenosis.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. (Pubmed Central) - Nov 18, 2020
Identification of critical risk factors for IRI and targeting them individually rather than one size fits all approach should be the major focus of future research. Various newer therapies like tocilizumab, anakinra, colchicine, revacept, and therapies targeting the reperfusion injury salvage kinase pathway, survivor activating factor enhancement, mitochondrial pathways, and angiopoietin-like peptide 4 hold promise for the future.
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Trial completion: ISAR-PLASTER: Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept (clinicaltrials.gov) - Apr 20, 2020
P2, N=334, Completed,
Various newer therapies like tocilizumab, anakinra, colchicine, revacept, and therapies targeting the reperfusion injury salvage kinase pathway, survivor activating factor enhancement, mitochondrial pathways, and angiopoietin-like peptide 4 hold promise for the future. Recruiting --> Completed
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Revacept, an Inhibitor of Platelet Adhesion in Patients With Symptomatic Carotid Artery Stenosis. Safety Data From the International Randomized Multicenter Revacept CS02 Phase 2 Study (Hall H) - Dec 21, 2019 - Abstract #ISC2020ISC_720;
Coronary intervention was necessary in 1 patient (0.6%) and 5 patients (3.1%), 24 hours and 3 months after Revacept infusion, respectively. These complications rates are comparable to the rate at day 30 follow up within the ICSS-study: ischemic stroke (91 patients 5.3%), intracerebral hemorrhage (8 patients, 0.5%) and any wound hematoma (81 patients, 4.7%) Conclusions The addition of Revacept to guideline-recommended anti-thrombotic therapy in patients with symptomatic stenosis of the internal carotid artery did not increase bleeding complications within the overall study population compared to previous studies.
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Trial completion date, Head-to-Head: Revacept/CS/02: Revacept in Symptomatic Carotid Stenosis (clinicaltrials.gov) - Dec 19, 2019
P2, N=158, Completed,
These complications rates are comparable to the rate at day 30 follow up within the ICSS-study: ischemic stroke (91 patients 5.3%), intracerebral hemorrhage (8 patients, 0.5%) and any wound hematoma (81 patients, 4.7%) Conclusions The addition of Revacept to guideline-recommended anti-thrombotic therapy in patients with symptomatic stenosis of the internal carotid artery did not increase bleeding complications within the overall study population compared to previous studies. Trial completion date: Oct 2018 --> Sep 2019
- |||||||||| Clinical, Journal: An update on novel antiplatelets in vascular patients. (Pubmed Central) - Nov 8, 2019
Other novel antiplatelets demonstrate positive results, but further studies focused on vascular patients are necessary. Novel experimental antiplatelets are still in early phases of the clinical and preclinical studies.
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR, Eliquis (apixaban) / BMS
Review, Journal: LMU Munich: platelet inhibition novel aspects on platelet inhibition and function. (Pubmed Central) - Jun 7, 2019
in Thromb Haemost 117:1240-1248), done at 33 sites in Europe. Furthermore, besides other ongoing clinical studies, we initiated and are currently recruiting patients for the multi-centre randomized APixaban versus PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF study as well as for the multi-centre phase II randomized, double-blind, placebo-controlled study of revacept in Patients With Stable Coronary Artery Disease (Revacept/CAD/02) trial.
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Trial completion, Head-to-Head: Revacept/CS/02: Revacept in Symptomatic Carotid Stenosis (clinicaltrials.gov) - Oct 17, 2018
P2, N=158, Completed,
Furthermore, besides other ongoing clinical studies, we initiated and are currently recruiting patients for the multi-centre randomized APixaban versus PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF study as well as for the multi-centre phase II randomized, double-blind, placebo-controlled study of revacept in Patients With Stable Coronary Artery Disease (Revacept/CAD/02) trial. Recruiting --> Completed
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Trial primary completion date, Head-to-Head: Revacept/CS/02: Revacept in Symptomatic Carotid Stenosis (clinicaltrials.gov) - Jan 18, 2018
P2, N=150, Recruiting,
Recruiting --> Completed Trial primary completion date: Sep 2017 --> Sep 2018
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Trial primary completion date, Head-to-Head: Revacept/CS/02: Revacept in Symptomatic Carotid Stenosis (clinicaltrials.gov) - Sep 25, 2015
P2, N=150, Recruiting,
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Sep 2017
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Trial initiation date, Head-to-Head: Revacept/CS/02: Revacept in Symptomatic Carotid Stenosis (clinicaltrials.gov) - May 16, 2013
P2, N=150, Recruiting,
Trial primary completion date: Sep 2014 --> Sep 2017 Initiation date: Jul 2012 --> Mar 2013
- |||||||||| Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) / advanceCOR
Enrollment open, Head-to-Head: Revacept/CS/02: Revacept in Symptomatic Carotid Stenosis (clinicaltrials.gov) - Oct 1, 2012
P2, N=150, Recruiting,
Initiation date: Jul 2012 --> Mar 2013 Not yet recruiting --> Recruiting
|
